Analysis of the Application of Sacubitril-Valsartan in Inpatients with Heart Failure in a Hospital

Abstract

Abstract:

〔Abstract〕 Objective： To analyze the application of sacubitril-valsartan in inpatients with heart failure in the First Affiliated Hospital of Dali University， so as to provide a basis for clinical rational use of the drug. Methods：The hospital information system was used to collect the basic information of inpatients who used sacubitril-valsartan from June to December 2020， and the application of the drug was retrospectively analyzed. Results： A total of 213 patients with indications were enrolled， and 42 cases had relative drug contraindications. The initial dose or frequency were unreasonable in 49 cases， and the target dose was not up to standard in 173 cases. There were 93 cases treated with ACEI or ARB converted to the application of sacubitril-valsartan， and 28 cases were not properly converted. Compared to the situation before treatment， the cardiac function of patients without relative contraindications improved significantly， while the renal function of patients with relative contraindications improved obviously. 49 cases had adverse drug reaction. Conclusion： There are some unreasonable situations in the use of sacubitril-valsartan in patients with heart failure in this hospital， such as relative medication contraindications， low initial dose， low rate of target dose reaches to standard， and inappropriate drug timing of drug conversion. It is suggested that medical institutions should standardize the clinical application of the drug.

Key words:

"> font-size:10.5pt, ">sacubitril-valsartan, heart failure, rational drug use, effectiveness, safety

CLC Number:

Li Qiujing, Guo Yu, Zhao Yanju, Shen Lei.

Analysis of the Application of Sacubitril-Valsartan in Inpatients with Heart Failure in a Hospital [J]. Journal of Dali University, 2022, 7(10): 22-27.

References

〔1〕李小荣，郑旭辉，李新立．血管紧张素受体脑啡肽酶抑制剂在心力衰竭治疗中的研究进展及展望〔J〕．中国循环杂志， 2018， 33（2）： 195-198.

〔2〕 YANCY C W， JESSUP M， BOZKURT B，et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure： A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America〔J〕. J Card Fail，2017，23（8）： 628-651.

〔3〕国家卫生计生委合理用药专家委员会，中国药师协会．心力衰竭合理用药指南（第2版）〔J〕. 中国医学前沿杂志（电子版）， 2019， 11（7）： 1-78.

〔4〕 PONIKOWSKI P， VOORS A A， ANKER S D，et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure： The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology （ESC）.Deve-loped with the Special Contribution of the Heart Failure Association（HFA） of the ESC〔J〕. Eur J Heart Fail，2016， 18（8）： 891-975.

〔5〕 MCMURRAY J J， PACKER M， DESAI A S， et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure〔J〕. N Engl J Med，2014，371（11）：993-1004.

〔6〕陈存芳，贾博，江珊，等．沙库巴曲缬沙坦治疗射血分数中间值心力衰竭患者的疗效及预后〔J〕. 中国新药与临床杂志，2020，39（2）： 88-92.

〔7〕 SOLOMON S D， ZILE M， PIESKE B， et al. The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction： A Phase 2 Double-Blind Randomised Controlled Trial〔J〕. Lancet，2012， 380： 1387-1395.

〔8〕 VADUGANATHAN M， CLAGGETT B L， DESAI A S，et al. Prior Heart Failure Hospitalization， Clinical Outcomes， and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF〔J〕. J Am Coll Cardiol， 2020， 75（3）：245-254.

〔9〕 DU A X， WESTERHOUT C M， MCALISTER F A， et al. Titration and Tolerability of Sacubitril/Valsartan for Patients with Heart Failure in Clinical Practice〔J〕. J Cardiovasc Pharmacol，2019，73（3）：149-154.

〔10〕 MARTENS P， LAMBEETS S， LAU C W，et al. Impact of Sacubitril/Valsartan on Heart Failure Admissions：Insights from Real-World Patient Prescriptions〔J〕. Acta Cardiol，2019，74（2）： 115-122.

〔11〕 VON LUEDER T G， SANGARALINGHAM S J， WANG B H，et al. Renin-Angiotensin Blockade Combined with Natriuretic Peptide System Augmentation： Novel Therapeutic Concepts to Combat Heart Failure〔J〕. Circ Heart Fail， 2013， 6（3）：594-605.

〔12〕 YANCY C W ， JANUZZI J L ， ALLEN L A ， et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment： Answers to 10 Pivotal Issues about Heart Failure with Reduced Ejection Fraction〔J〕.J Am Coll Cardiol， 2017：S073510971741641X.

〔13〕 MCMURRAY J J， PACKER M， DESAI A S， et al. Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure： Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Mortality in Heart Failure Trial（PARADIGM-HF）〔J〕. Eur J Heart Fail， 2013，15（9）：1062-1073.

[1]	Xie Diyang, Peng Zhijie. On the Extraterritorial Jurisdiction in the International Environmental Civil Public Interest Litigation [J]. Journal of Dali University, 2022, 7(7): 46-55.
[2]	Zhang Huan. The Dilemma and Outlet of Cambodian Chinese Education under the Background of Belt and Road Initiative [J]. Journal of Dali University, 2022, 7(7): 104-108.
[3]	Ou Ling, Li Cailin, Li Yinrui, Zhou Jie, Shan Wanxin, Wu Dingyu, Peng Fang. In vitro Study on the Periplaneta americana Polypepticde PAE2 Reversing Multi-Drug Resistance of BEL-7402/5-FU Based on AMPK-Regulated Autophagy [J]. Journal of Dali University, 2022, 7(4): 1-7.
[4]	Qing Chen, Chen Jinghu, Li Bolong, Liu Heng, Zhang Chenggui. Comparative Analysis of Liposoluble Constituents in the Larvae and Adults of Black Soldier Fly by GC-MS [J]. Journal of Dali University, 2022, 7(4): 8-11.
[5]	Wang Ruihang, Liu Xiaobo, Liao Ｓi, Hua Peng. Meta-Analysis of Cutaneous Adverse Reactions Induced by Dabrafenib Combined with Trametinib in the Treatment of Melanoma [J]. Journal of Dali University, 2022, 7(4): 12-20.
[6]	Hong Wenjuan, Zou Jiulin, Yu Zhuorui, Cheng Jiamao, He Minhua. Effects of SGLT2i on Bone Metabolism in Nephrotic Syndrome Model Rats [J]. Journal of Dali University, 2022, 7(4): 21-25.
[7]	Li Bin, Li Sufen, Yang Na, Xiong Wei. Expression and Significance of THBS2 Gene mRNA in Human Malignant Pleural Mesothelioma Based on Tumor Databases [J]. Journal of Dali University, 2022, 7(4): 26-33.
[8]	Duan Yi, Ni Changwen, Wang Minhua, Sun Sujiao, Huang Ling. Effects of the 7-Hydroxyisoflavone in the Proliferative Activity of HaCaT Cells and UVB-induced Photodamage [J]. Journal of Dali University, 2022, 7(4): 34-39.
[9]	Huang Zhong, Jia Ruipeng, Liu Yiheng, Zhang Chao, Liu Ke. Analysis of Risk Factors for Bone Cement Leakage during Percutaneous Kyphoplasty [J]. Journal of Dali University, 2022, 7(4): 40-43.
[10]	Luo Xinlei, Zhao Hui, Bai Tao, Xu Song, Zhang Xiongwen, Na Qiang. Analysis of Influencing Factors of New Fractures after Osteoporotic Vertebral Compression Fracture Surgery [J]. Journal of Dali University, 2022, 7(4): 44-46.
[11]	Xu Sanxiong, Zhang Jiyuan, Ma Xueying, Wei Guosong, Li Lin. Comparison of Curative Effects of MIS-TLIF and PLIF in the Treatment of Single-Segment Lumbar Degenerative Diseases [J]. Journal of Dali University, 2022, 7(4): 47-51.
[12]	Liu Siyuan, Rao Tao, Zhao Heng, Dou Jichen, Zhou Yi, Liu Qinghua, Cun Ｘinhua, . Clinical Evaluation of Oblique Lateral Interbody Fusion in the Treatment of Elderly Patients with Lumbar Tuberculosis [J]. Journal of Dali University, 2022, 7(4): 52-56.
[13]	Hu Jianhua, Hu Qi, Gao Guoxi, Lian Xingye, Yang Zhao, Zhang Chao. Analysis of the Treatment of Early Incision Deep Infection after Posterior Lumbar Internal Fixation and Fusion [J]. Journal of Dali University, 2022, 7(4): 57-59.
[14]	Gao Guoxi, Lian Xingye, Liu Weibing, Zhang Jun, Hu Jianhua, Lei Yunkun, Yang Zhao, Zhang Chao. Analysis of Clinical Treatment of Lumbar Brucellosis [J]. Journal of Dali University, 2022, 7(4): 60-62.
[15]	Peng Yunchuan, Luo Ting, Qi Lin, Ma Hongbing. Clinical Application of Improved Preoperative Preparation Method for DAA Total Hip Arthroplasty [J]. Journal of Dali University, 2022, 7(4): 63-65.